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Blast phase in chronic myelogenous leukemia (CML) has rarely been reported to involve extramedullary sites like skin,
lymph nodes, and central nervous system. Clinical history, characteristic hematologic findings (elevated leukocyte counts,
myelocytic predominance, and basophilia), and Philadelphia chromosome are of high diagnostic significance especially in isolated
extramedullary presentations. We describe a unique case of CML relapse with blast phase involving the eye. A 66-year-old man
with a known diagnosis of CML on imatinib and in molecular remission for 3 years presented with a painful blind eye. Histologic
examination revealed diffuse involvement of choroid, iris, vitreous humor, and the optic nerve by blast cells. The blasts expressed
CD34, aberrant TdT, and a myeloid phenotype (CD13, CD33, and CD117). Fluorescence in situ hybridization (FISH) of vitreous
fluid detected BCR-ABL1 gene rearrangement. Additionally, trisomy 8 and gains of 9 and 22 were seen which were not present in
the initial diagnostic marrow study 3 years ago. At relapse, the bone marrow, peripheral blood, and the cerebrospinal fluid were
not involved by CML. Patient received induction chemotherapy and single dose prophylactic intrathecal methotrexate and was
maintained on antityrosine kinase therapy and eventually underwent allogenic stem cell transplantation.
1. Introduction
Blast crisis in CML is defined by the presence of ≥20% blasts
in the bone marrow or peripheral blood, large clusters of
blasts in the bonemarrow biopsy, or any extramedullary blast
proliferation [1]. Extramedullary disease occurs in a small
percent of CML cases and is found to manifest in its chronic,
accelerated, or blast phase [2, 3]. It can occur at various sites
including bone, lymph node, skin, soft tissue, and central
nervous system (CNS) [3–6]. We describe an unusual case
of relapsed chronic myelogenous leukemia (CML) in blast
crisis presenting with isolated ocular involvement in a patient
undergoing imatinib therapy and hematologically in mor-
phologic, cytogenetic, andmolecular remission at the time of
relapse.
2. Case Presentation
Our patient is a 66-year-old male who was first diagnosed
with CML after presenting to the emergency room with
acute onset knee pain. During the investigation, he was
found to have an elevated white blood cell count (64.4 ×
109/L). The differential count revealed neutrophilia with left
shift and basophilia. A subsequent bone marrow biopsy
showed morphologic features consistent with chronic phase
of CML. Conventional karyotyping and fluorescence in situ
hybridization (FISH) on the bone marrow aspirate (Figure 9)
showed evidence of t(9;22) BCR-ABL1 rearrangement and
real time quantitative PCR was positive for M-BCR/ABL
t(9;22), p210 fusion transcript. The patient was started on
imatinib 400mg once a day. He achieved major molecular
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Figure 1: Gross photomicrograph depicting pupil-optic nerve (PO)
section of enucleated eye which reveals diffuse thickening of the iris
and part of the choroid layer.
response after 3 months of therapy and was followed up
every 3-4 months thereafter withM-BCR/ABL [t(9;22), p210]
fusion gene transcript levels in peripheral blood by real time
quantitative PCR.
He remained in remission for three years after initial
diagnosis, when he presented with sudden onset pain and
loss of vision in the right eye. Magnetic resonance imag-
ing (MRI) scan showed significant intraorbital and optic
nerve enhancement. An infratemporal intraconal fat and
intraorbital fat biopsy was negative for malignancy. The
patient’s symptoms improved with conservativemanagement
by posterior chamber decompression and steroid therapy but
his vision never returned to baseline following this episode.
A follow-up MRI 2 months later showed no residual signs
of enhancement. Eight months following this episode, he
presented with recurrent pain in the right eye, which did
not resolve with conservative management. As a result, the
patient underwent enucleation of his right eye.
On gross examination, a cross section of the eye
showed diffuse circumferential thickening of the choroid
(Figure 1). Microscopic examination revealed dense infil-
tration of the choroid and iris and optic nerve margin by
a monotonous mononuclear cell infiltrate morphologically
resembling blasts (Figures 2 and 3). By flow cytometry (Fig-
ure 4), the blasts were positive for CD34 and demonstrated
myeloid immunophenotype expressing CD13, CD33, and
CD11c. Blasts were negative for specific lymphoid markers
including CD19, CD20, CD79a, CD2, cytoplasmic CD3,
CD5, and CD10. However, CD7 was aberrantly coexpressed
by the blasts. Interestingly, the blasts did not show cyto-
plasmic myeloperoxidase (MPO) and terminal deoxynu-
cleotidyl transferase (TdT) expression by flow cytometry.
By immunohistochemical staining (Figures 5–7), the blasts
were positive for CD34 (Figure 5) with focal expression
of variable intensity for CD117 (Figure 6) and strong and
diffuse expression of TdT (Figure 7) but were negative for
B- or T-lineage lymphoid antigen markers (CD20, CD3, and
CD79a) (not shown). MPO expression was focal and weak
Figure 2: Blasts cells infiltrating the iris (H&E, magnification ×20).
Figure 3: Sheets of monotonous mononuclear blast cells (H&E,
magnification ×400).
(not shown). FISH cytogenetic analysis on vitreous fluid
(Figure 8) demonstrated presence ofBCR/ABL1 [t(9;22)] gene
rearrangement identical to the abnormalities detected in the
original bone marrow (Figure 9) in which the diagnosis of
CML was rendered. In addition to Philadelphia chromosome
(Ph), a complex karyotype including trisomy 8 and gain of
chromosomes 9 and 22 was also detected in this analysis.
In view of the patient’s history, a diagnosis of CML in
blast phase was rendered. A subsequent bone marrow exam
showed no morphologic, cytogenetic, or molecular evidence
of CML or acute leukemia. Cytological evaluation and flow
cytometry of cerebrospinal fluidwere also negative for disease
involvement. The patient underwent induction therapy with
idarubicin and cytarabine and a single dose of intrathecal
methotrexate. He was maintained on dasatinib 150mg daily
but was switched back to imatinib due to intolerance to
dasatinib. He subsequently underwent allogenic stem cell
transplantation after 5 months.
3. Discussion
Extramedullary blast crisis in CML is a rare occurrence. In
a study of 235 CML patients by Specchia et al. [2], 16%
developed extramedullary blast crisis. While both myeloid
and lymphoid blast transformations are described, 80% of
transformations are ofmyeloid origin, whereas lymphoblastic
transformations account for approximately 20%. Among the
latter, B-lymphoblastic transformations are more common
than T-lymphoblastic crisis [4, 7]. A recent study looking
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Figure 4: Flow cytometric immunophenotypic analysis of vitreous fluid: blast gate (P4 gate in the top line) represents the dim CD45+ cells
with low side light scatter (SSC). Blast gate (P3 gate in the bottom line) represents the same population of blasts analyzed for cytoplasmic
markers in a separate tube. The distinct cluster of blasts (red color population) exhibit the following immunophenotypic characteristics:
positive for CD34, CD117, CD7, CD11b, CD13 (dim), and CD33; negative for CD19, CD10, CD20, CD3, CD5, CD15, CD16, CD61, CD235a,
HLA-DR, CD14, cytoplasmic CD3, cytoplasmic CD79a, cytoplasmic MPO, and cytoplasmic TdT.
at outcomes found no significant difference in overall sur-
vival of CML in myeloid versus lymphoid blast crisis [7].
Ocular manifestations as presenting feature of CML have
been previously described. The first case report of ocular
involvement by CML in blast phase was published by Alegre
et al. [8] but the patient had evidence of disease at other
sites. Isolated ocular blast crisis was first described by Lipton
et al. [9], who reported a case of relapsed CML presenting
as lymphoid blast crisis. In their patient, lymphoid blast
crisis was also the initial presentation of the disease at the
time of diagnosis. Conversely, our patient initially presented
in chronic phase of CML and relapsed with myeloid blast
crisis in the eye. Immunophenotypically by flow cytometry,
the blasts expressed CD34, CD13, and CD33 with a subset
expressing CD117 whereas they were negative for cytoplasmic
MPO, TdT, and B- (CD19, CD22, CD79a, andCD10) as well as
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Figure 5: CD34 immunohistochemistry: sheets of monotonous
CD34 positive blast cells (magnification ×400).
Figure 6: CD117 immunohistochemistry: focal and variable inten-
sity of CD117 expression is seen in the blasts (magnification ×400).
Figure 7: TdT immunohistochemistry: sheets of blasts showing
nuclear expression of TdT (magnification ×400).
T-lymphoid antigen markers (cytoplasmic CD3). In contrast
to flow cytometry, the blasts were strongly and uniformly
positive for TdT by immunohistochemistry. The reason for
this discrepancy is not entirely clear but we speculate that the
lack of TdT expression by flow cytometrymay be attributed to
failure of permeabilization step in the protocol for assessment
of cytoplasmic markers. The lack of expression of lymphoid
markers and positivity for CD13, CD33, and CD117 was
consistent with myeloid immunophenotype for the blasts.
In our case, the patient was treated with cytarabine/doxo-
rubicin and intrathecal methotrexate. Imatinib mesylate is
considered first-line therapy for treatment of CML in chronic
Figure 8: Fluorescence in situ hybridization assay on vitreous
humor smear shows two BCR-ABL1 fusion signals, one BCR probe
signal, and two ABL1 probe signals; thus a t(9;22) BCR-ABL1 gene
rearrangement with gains of 9 and 22 [orange = 9q34 ABL1 probe;
green = 22q11.2 BCR probe].
Figure 9: Fluorescent in situ hybridization on original diagnostic
bone marrow aspirate shows one BCR-ABL1 fusion signal, two BCR
probe signals, and three ABL1 probe signals in 90.5% of interphase
cells.
phase with majority of patients achieving complete cytoge-
netic and major molecular response. Sudden evolution of
disease into blast phase can rarely occur while the patient
is on imatinib therapy [10]. Isolated CNS involvement by
CML in blast phase has been reported in patients receiving
imatinib mesylate treatment [11, 12]. It usually presents as a
relapse following an initial complete remission on imatinib
or after bone marrow transplant. In some patients, there
may be no signs of disease involvement in the blood and
bone marrow at time of CNS manifestation [12]. The central
nervous system is relatively prone to disease involvement
while on imatinib therapy and this is attributed mainly to
poor permeability of imatinib through the blood brain barrier
[11, 13]. The most common sites of CNS involvement are the
lateral ventricular walls [14], meninges [15], and the optic
nerve [16], causing symptoms such as headache, cognitive
changes, raised intracranial pressure, and visual disturbances.
Intraocular optic nerve involvement has been associated
with poor prognosis and impermeability to intrathecal
chemotherapeutic agents [17]. Increasing reports of CNS
involvement by CML in different phases have necessitated
broader disease monitoring, including BCR-ABL gene quan-
tification in CSF [14]. Second-generation tyrosine kinase
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inhibitors (TKI) such as dasatinib are more effective in
treating CNS disease [18] due to better penetration of the
blood brain barrier [19]. For these reasons, dasatinib and
nilotinib are now FDA-approved as first-line therapy in CML
[20].
In our patient, the chromosome study was positive
for t(9;22)(q34;q11) translocation, FISH showed BCR/ABL
fusion gene, and RT-PCR assay was positive for major
BCR-ABL mRNA expression. His previously documented
diagnosis of chronic phase CML was helpful in diagnosing
his ocular blast proliferation/myeloid sarcoma as a blast phase
of CML rather than a genetically different de novo acute
myeloid leukemia [4, 21, 22]. While blast proliferation in
an extramedullary setting would be most consistent with
a diagnosis of myeloid sarcoma, since our patient had a
documented history of CML, we preferred to use the term
blast phase of CML to guide therapeutic decisions. While
t(9;22)(q34;q11) translocation is most commonly associated
with CML or precursor B-ALL, its presence can be rarely seen
in acute myeloid leukemia with a reported incidence of 1-
2% of all AML cases. In the absence of a prior chronic or
accelerated phase of CML, distinction between blast phase
of CML and Philadelphia chromosome-positive (Ph+) AML
can be difficult, as they exhibit a major overlap in their
clinical presentation and genetic features [23]. Nevertheless,
presence of splenomegaly, basophilia, and chromosomal
abnormalities in addition to Philadelphia chromosome and
a previous history of chronic or accelerated phase CML have
all been attributed to blast phase of CML over Ph+ AML
[24, 25].
At the time of relapse, in addition to t(9;22)(q34;q11)
reciprocal translocation (Ph+), our patient demonstrated
other chromosomal aberrancies including trisomy 8 and
gains of chromosomes 9 and 22. Trisomy 8 has been fre-
quently associated with clonal evolution in CML patients
on imatinib who are otherwise in complete cytogenetic
remission [26]. At the genetic level, trisomy 8 has been linked
to alterations of MYC located at 8q24 [26]. Interestingly,
no MYC alterations were detected in our patient. Gains of
chromosomes 9 and 22 appear to be nonrandom chromoso-
mal aberrations and perhaps contribute to overall genomic
instability; however, the mechanisms of clonal evolution in
CML are not well understood.
Using whole genome sequencing, Calabretta and Perrotti
[26] found mutations in 9 genes, including GATA2, MAX,
ENO1, and ANO5, which were linked to progression of
CML to blast phase. Gain-of-function mutations in GATA2
were described in a previous study which reported myeloid
blast transformation in CML [27]. MAX gene, through its
complex interactions with MYC [28] and CEBPA [29], has
been linked to tumor progression [30]. ENO1 acts as a tran-
scriptional repressor ofMYC [31]. Recently it has been shown
that transcription regulators, including Hes1 and Evi1, are
involved in disease progression and even confer resistance to
tyrosine kinase inhibitors [32, 33]. Many recent studies have
identified potential markers as a means of better monitoring
of disease progression. SYK gene activation is one such poten-
tial marker of disease progression and dasatinib resistance
[34, 35].
4. Conclusions
While extramedullary manifestation of CML is rare, a high
degree of suspicion is warranted in patients with CML on
imatinib therapy who manifest CNS or ocular symptoms,
even in the absence of any hematologic, cytogenetic, or
molecular evidence of disease. Despite advances inmolecular
disease detection, more sensitive and effective methods of
monitoring disease progression are still needed.
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